Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Last month, Illumina Inc (NASDAQ:ILMN) had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.
上個月，Illumina公司（納斯達克代碼爲ILMN）不得不放棄Grail公司。然而，這家DNA測序公司已經收購了Fluent BioSciences以擴大其在單細胞分析和多組學研究方面的影響力。
Launched in 2018, Fluent was backed by Illumina's venture capital arm. Other investors include Samsara Biocapital, Civilization Ventures, Co-win Ventures and VC23.
Fluent於2018年推出，並得到了Illumina的創投支持。其他投資者包括Samsara Biocapital、Civilization Ventures、Co-win Ventures和VC23。
While the financial details were not disclosed, the company said the deal was closed and funded with cash it had on hand.
雖然財務細節並未披露，但公司表示這筆交易已經完成，並用手頭現金進行了融資。
At the close of the first quarter, the company held $1.115 billion in cash, cash equivalents and short-term investments.
在第一季度結束時，公司持有11.15億美元的現金、現金等價物和短期投資。
Fluent's single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables.
Fluent的單細胞分析技術消除了複雜、昂貴的儀器和微流控消耗品的需求。
Related: Gene Sequencing Firm Illumina Escapes Carl Icahn's Second Proxy Battle Amid Grail Divestment Efforts.
相關內容：基因測序公司Illumina在Grail出售努力中成功逃過Carl Icahn的第二次代理戰爭。
Fluent's latest release, PIPseq V, enables the detection of cell types often missed with current methods and the highest scalability, capable of processing a range from 100 cells up to 1 million.
Fluent的最新版本PIPseq V，能夠檢測常被現有方法遺漏的細胞類型，並具有最高可擴展性，能夠處理從100個細胞到100萬個細胞的區間。
The Fluent team will join Illumina, and PIPseq V will be integrated into Illumina's product portfolio. The company plans to build on Fluent's technology to develop full end-to-end solutions for single-cell analysis.
Fluent團隊將加入Illumina，並將PIPseq V集成到Illumina的產品組合中。該公司計劃基於Fluent的技術開發全面的單細胞分析端到端解決方案。
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
Illumina的首席技術官Steven Barnard表示：“Fluent BioSciences加入Illumina將爲我們的客戶在關鍵增長領域提供重要且新穎的能力，並推進我們的多組學增長策略。單細胞研究開啓了發現新領域的大門，Fluent的創新、易於使用和靈活的單細胞方法將加速我們爲客戶提供全面的多組學解決方案的能力。”
Analyst Reaction:
分析師反應：
- Citigroup upgrades Illumina from Neutral to Buy, with a price target of $140.
- Stephens reiterates Illumina with an Overweight and maintains a price target of $170.
- 花旗集團將Illumina從中立評級調升爲買入，目標價爲140美元。
- Stephens重申對Illumina的超配評級，並保持170美元的目標價。
Price Action: ILMN shares are up 5.68% at $112.73 at last check Wednesday.
價格行動：截至上週三最後一次查詢，ILMN股價上漲5.68%，至112.73美元。
Photo via Shutterstock
圖片來自shutterstock。
- Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ.
- 曾被估值約爲70億美元的癌症血液檢測開發商Grail即將開始在納斯達克交易。